Research Topics
| Sandra M SwainSummaryCountry: USA Publications
| Collaborators
|
Detail Information
Publications
A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancerPeter F Lebowitz
Medical Oncology Clinical Research Unit, Cancer Therapeutics Branch, Laboratory of Pathology, Biostatistics and Data Management, and Surgery Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
Clin Cancer Res 10:6764-9. 2004..CONCLUSIONS: Docetaxel/capecitabine is a highly active regimen in the neoadjuvant setting. Neoadjuvant therapy with 75 mg/m(2) docetaxel and 1600 mg/m(2)/day days 2-15 is recommended...- Emerging drugs to replace current leaders in first-line therapy for breast cancerMichael C Cox
National Cancer Institute - National Institutes of Health, Breast Cancer Section, Medical Oncology Branch, Center for Cancer Research, Bethesda, MD, USA
Expert Opin Emerg Drugs 11:489-501. 2006..These agents have increased excitement in the treatment of breast cancer and stand on the forefront of a potential improvement in quality of life and treatment options for patients afflicted with this deadly disease... - Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and managementSandra M Swain
Washington Cancer Institute, Washington Hospital Center, Washington, DC 20010, USA
Clin Adv Hematol Oncol 6:455-67. 2008..This article provides an overview of the incidence, characteristics, and management of MTI-associated neurotoxicities for known vinca alkaloids and taxanes, as well as newer agents, such as vinflunine and ixabepilone... 
Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancerSherry X Yang
National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
Clin Cancer Res 14:5893-9. 2008..To identify biomarkers and gene expression profile signatures to distinguish patients with partial response (PR) from those with stable disease (SD) and progressive disease (PD)...
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 studySandra M Swain
Washington Cancer Institute, Medstar Washington Hospital Center, Washington, DC, USA Electronic address
Lancet Oncol 14:461-71. 2013..Interim analysis of overall survival favoured the pertuzumab group but was not significant. Here, we report results for overall survival after an additional year of follow-up...- Longer therapy, iatrogenic amenorrhea, and survival in early breast cancerSandra M Swain
National Surgical Adjuvant Breast and Bowel Project, Washington Cancer Institute at Washington Hospital Center, Washington, DC 20010, USA
N Engl J Med 362:2053-65. 2010..The effectiveness of concurrent versus sequential regimens is not known... - Chemotherapy: updates and new perspectivesSandra M Swain
Washington Cancer Institute, Washington Hospital Center, Washington, District of Columbia 20010, USA
Oncologist 15:8-17. 2010..This paper discusses recent data, including new trials that are more fully incorporating current knowledge with respect to molecular markers and the underlying biology of breast cancer... - Chemotherapy: updates and new perspectivesSandra M Swain
Washington Cancer Institute, Washington Hospital Center, Washington, District of Columbia 20010, USA
Oncologist 16:30-9. 2011..This paper discusses recent data, including new trials that are more fully incorporating current knowledge with respect to molecular markers and the underlying biology of breast cancer... - Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trialSandra M Swain
National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA, USA
Breast Cancer Res Treat 113:315-20. 2009..These results can be used to inform premenopausal women about the risk and time course of amenorrhea associated with this common adjuvant therapy regimen, along with the effects on symptoms and QOL... - Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trialPatricia A Ganz
National Surgical Adjuvant Breast and Bowel Project Operations Center NSABP, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA
J Clin Oncol 29:1110-6. 2011..The National Surgical Adjuvant Breast and Bowel Project B-30 trial included menstrual history (MH) and quality-of-life (QOL) studies to compare treatments on these outcomes... - Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast canElizabeth Tan-Chiu
National Surgical Adjuvant Breast and Bowel Project (NSABP, University of Pittsburgh, PA, USA
J Clin Oncol 23:7811-9. 2005..CONCLUSION: Administering trastuzumab with paclitaxel after AC increases incidence of CHF and lesser CD. Potential cardiotoxicity should be carefully considered when discussing benefits and risks of this therapy... - Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research GroupPriya Rastogi
National Surgical Adjuvant Breast and Bowel Project, Four Allegheny Center, Pittsburgh, PA 15212, USA
Clin Breast Cancer 11:228-34. 2011..The purpose of this trial was to determine the activity and safety profile of neoadjuvant bevacizumab with chemotherapy in women with locally advanced breast cancer (LABC)... - Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal grEdward H Romond
National Surgical Adjuvant Breast and Bowel Project, East Commons Professional Building, Four Allegheny Center, 5th Floor, Pittsburgh, PA 15212, USA
J Clin Oncol 30:3792-9. 2012..Given the demonstrated efficacy of trastuzumab, ongoing assessment of cardiac safety and identification of risk factors for CD are important for optimal patient care... - Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24D Craig Allred
National Surgical Adjuvant Breast and Bowel Project, Washington University School of Medicine, Department of Pathology and Immunology, 660 Euclid Campus Box 8118, St Louis, MO 63110, USA
J Clin Oncol 30:1268-73. 2012..Patients were enrolled without knowledge of hormone receptor status. The current study retrospectively evaluated the relationship between receptors and response to tamoxifen... - Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancerEdward H Romond
National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
N Engl J Med 353:1673-84. 2005..CONCLUSIONS: Trastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide improves outcomes among women with surgically removed HER2-positive breast cancer. (ClinicalTrials.gov numbers, NCT00004067 and NCT00005970.).. - A phase II clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancerSheri K Dennison
Walter Reed Army Medical Center, 6900 Georgia Ave NW, Washington, DC 20307, USA
Invest New Drugs 25:545-51. 2007..The combination of gefitinib and docetaxel is an active regimen in patients with previously untreated metastatic breast cancer, with a clinical benefit rate and toxicity profile in the range of that reported for docetaxel alone... - Cardiac Tolerability of Pertuzumab Plus Trastuzumab Plus Docetaxel in Patients With HER2-Positive Metastatic Breast Cancer in CLEOPATRA: A Randomized, Double-Blind, Placebo-Controlled Phase III StudySandra M Swain
Washington Cancer Institute, Medstar Washington Hospital Center, Washington, D C, USA
Oncologist 18:257-64. 2013..The majority of cardiac adverse events were reversible... - Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trialAlexander H G Paterson
National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA, USA
Lancet Oncol 13:734-42. 2012..The National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol B-34 aims to ascertain whether oral clodronate can improve outcomes in women with primary breast cancer... - The impact of systemic therapy following ductal carcinoma in situJennifer Eng-Wong
Department of Internal Medicine, Division of Oncology, Lombardi Cancer Center, Georgetown University, Washington, DC, USA
J Natl Cancer Inst Monogr 2010:200-3. 2010..We review the results of the phase III trials of tamoxifen in DCIS as well as the emerging risk reduction therapies... - Cardiovascular complications of breast cancer therapySandra M Swain
Washington Cancer Institute, Washington Hospital Center, Washington, DC, USA
Clin Adv Hematol Oncol 6:247-8, 282. 2008 - Evaluation of lymphangiogenic factors, vascular endothelial growth factor D and E-cadherin in distinguishing inflammatory from locally advanced breast cancerPaul H Levine
George Washington University School of Public Health and Health Services, Washington, DC 20037, USA
Clin Breast Cancer 12:232-9. 2012..Inflammatory breast cancer (IBC) is an aggressive form of breast cancer that on presentation resembles locally advanced breast cancer (LABC). This study identified molecular features of IBC and LABC to investigate pathogenesis... - Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancerChia C Portera
Medical Oncology Branch, National Cancer Institute, Bethesda, MD, USA
Clin Cancer Res 14:2710-6. 2008..To evaluate safety and efficacy of trastuzumab with pertuzumab in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who had progressive disease on trastuzumab-based therapy... - Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanesNeelima Denduluri
Breast Cancer Section, Medical Oncology Branch and Biostatistics, Office of the Clinical Director, Center for Cancer Research, National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, Bethesda, MD, USA
J Clin Oncol 25:3421-7. 2007..Ixabepilone was evaluated for efficacy and safety in a phase II clinical trial for women with metastatic breast cancer... - A novel case of bisphosphonate-related osteonecrosis of the torus palatinus in a patient with metastatic breast cancerMatthew L Goldman
Breast Cancer Section, Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20889, USA
Oncology 71:306-8. 2006..This case demonstrates that patients with a torus palatinus may be at high risk for osteonecrosis, and reinforces the need for good oral hygiene and frequent dental examination while receiving bisphosphonate therapy... - The heart of the matterChia C Portera
J Clin Oncol 25:3794-6. 2007 - Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab--initial experienceArpi Thukral
Medical Oncology Branch, Molecular Imaging Program, and Biostatistics and Data Management Section, Center for Cancer Research, NCI, and Diagnostic Radiology Department, Warren G Magnuson Clinical Center, NIH, Bethesda, MD 20889 5015, USA
Radiology 244:727-35. 2007.... - Circulating biomarkers of bevacizumab activity in patients with breast cancerNeelima Denduluri
Breast Cancer Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Heath, Bethesda, Maryland, USA
Cancer Biol Ther 7:15-20. 2008..Tumor samples were evaluated for VEGFR-2 mutations before and after bevacizumab... - Cardiac toxicity in breast cancer survivors: review of potential cardiac problemsBrian R J Healey Bird
Breast Cancer Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, MD, USA
Clin Cancer Res 14:14-24. 2008..This review examines the cardiac toxicity of adjuvant therapy, monitoring for early changes and existing guidelines for monitoring cardiac function in patients with breast cancer... - Multiplexed cell signaling analysis of human breast cancer applications for personalized therapyJulia D Wulfkuhle
Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia 20110, USA
J Proteome Res 7:1508-17. 2008..Analysis of biopsy material from clinical trials for targeted therapeutics demonstrates the feasibility and utility of comprehensive signal pathway activation profiling for molecular analysis... - Locally advanced and inflammatory breast cancerStephen Chia
Department of Medical Oncology, British Columbia Cancer Agency, 600 West 10th Ave, Vancouver, British Columbia, Canada
J Clin Oncol 26:786-90. 2008 - CA 125 elevation in breast cancer: a case report and review of the literatureGregory D Leonard
Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
Breast J 10:146-9. 2004..Further information on CA 125 in breast cancer is required to delineate its role in the management of this disease... - Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancerJanice M Walshe
Breast Cancer Section, Medical Oncology Branch, Center for Cancer Research National Cancer Institute, National Institutes of Health, Bethesda, MD 20889, USA
J Clin Oncol 24:5769-79. 2006.... - Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancerNeelima Denduluri
Breast Cancer Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Heath, Bldg 8, Rm 5101, 8901 Wisconsin Ave, Bethesda, MD 20889 5015, USA
Invest New Drugs 25:63-7. 2007..Although ixabepilone was well-tolerated, the dose of 8-10 mg/m(2) daily for 3 days is not an effective therapy in metastatic breast cancer previously exposed to taxanes... - Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapyJennifer A Low
Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bldg 8, Rm 5101, 8901 Wisconsin Ave, Bethesda, MD 20889-5015, USA
J Clin Oncol 22:4067-74. 2004..CONCLUSION: Fifteen-year follow-up of stage IIIA and inflammatory breast cancer is rarely reported; IBC patients have a poor long-term outlook... - Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancerAntoinette R Tan
Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20889, USA
Clin Cancer Res 10:5038-47. 2004..Dose escalation of a 1-hour infusion of flavopiridol with docetaxel was also not possible. The changes in p53 and phospho-Rb in buccal mucosa suggest that a biological effect with flavopiridol was achieved... - Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitorAntoinette R Tan
Cancer Therapeutics Branch, Medical Oncology Clinical Research Unit, Center for Cancer Research, National Cancer Institute, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20889, USA
J Clin Oncol 22:3080-90. 2004..The lack of reduced tumor proliferation may be attributed to the heterogeneous expression of receptor in the EGFR-positive patient and absence of target in this cohort of heavily pretreated patients... - Ductal carcinoma in situ, complexities and challengesGregory D Leonard
Cancer Therapeutics Branch, National Cancer Institute, Bethesda, MD 20889-5105, USA
J Natl Cancer Inst 96:906-20. 2004..Ongoing and recently completed studies should provide information on outcomes in patients treated with lumpectomy alone and on the effectiveness of aromatase inhibitors as an alternative to tamoxifen... - Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancerSandra M Swain
National Cancer Institute, Bethesda, MD, USA
J Natl Cancer Inst 96:516-23. 2004.... - Rationale and clinical trial design for evaluating gemcitabine as neoadjuvant and adjuvant therapy for breast cancerEleftherios P Mamounas
Cancer Center, Aultman Health Foundation, Canton, OH 44710, USA
Clin Breast Cancer 4:S121-6. 2004..These trials will be important in establishing a role for this agent in the adjuvant setting and will hopefully lead to the development of more effective adjuvant chemotherapy regimens in the future... - Ongoing adjuvant trials with trastuzumab in breast cancerAntoinette R Tan
Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20889, USA
Semin Oncol 30:54-64. 2003..For now, the use of trastuzumab as adjuvant therapy is still investigational, but its integration has tremendous potential to improve treatment outcomes in patients with primary breast cancer... - Liquid-chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitorErin R Lepper
Clinical Pharmacology Research Core, Medical Oncology Clinical Research Unit, and Cancer Therapeutics Branch, National Cancer Institute, 9000 Rockville Pike, Building 10, Room 5A01, Bethesda, MD 20892, USA
J Chromatogr B Analyt Technol Biomed Life Sci 796:181-8. 2003..2% and 2.13 to 5.10%, respectively, for three different sets of quality control samples. The developed method was successfully applied to study the pharmacokinetics of erlotinib in a cancer patient at the recommended daily dose of 150 mg... - Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancerNicole J McCarthy
Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20889, USA
Clin Cancer Res 8:3857-62. 2002..02; Bonferroni test). CONCLUSIONS: These data suggest that there is an increased MVD in breast cancer with the inflammatory phenotype as compared with breast cancer without the inflammatory phenotype... - Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasmsAntoinette R Tan
Center for Cancer Research, Developmental Therapeutics Program, and Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD 20892, USA
J Clin Oncol 20:4074-82. 2002..Further studies to determine the optimal schedule of flavopiridol as a single agent and in combination with chemotherapeutic agents are underway... - Oophorectomy in carriers of BRCA mutationsSen H Zhuang
N Engl J Med 347:1037-40; author reply 1037-40. 2002 - Contralateral breast cancer: where does it all begin?Suparna Bonthala Wedam
J Clin Oncol 23:4585-7. 2005 - Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancerJennifer A Low
Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20889-5015, USA
J Clin Oncol 23:2726-34. 2005..Sensory neuropathy was mild with grade 3 neurotoxicity rarely seen. Microtubule stabilization occurred in tumor biopsies after treatment with ixabepilone... - Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxelMichael C Cox
Clinical Pharmacology Research Core, National Cancer Institute, Bethesda, Maryland 20889, USA
Clin Cancer Res 12:4636-40. 2006..CONCLUSIONS: This study indicates that garlic does not significantly affect the disposition of docetaxel. However, it cannot be excluded that garlic decreases the clearance of docetaxel in patients carrying a CYP3A5*1A allele... - Clinical aspects of inflammatory breast cancerJanice M Walshe
Breast Cancer Section, Medical Oncology Branch, Centre for Cancer Research, National Cancer Institute, National Institute of Health, MD 20889, USA
Breast Dis 22:35-44. 2005..This review addresses the historical milestones and clinical characteristics involved in the differentiation of IBC and briefly discusses the emerging molecular data that may facilitate the distinction of IBC from LABC... - A step in the right directionSandra M Swain
J Clin Oncol 24:3717-8. 2006 - Changes in neurologic function tests may predict neurotoxicity caused by ixabepiloneJames J Lee
Cancer Therapeutics Branch, Medical Oncology Clinical Research Unit, and Biostatistics and Data Management Section, Center for Cancer Research, Cancer Therapy Evaluation Program, National Institutes of Health, Bethesda, MD 20889-5015, USA
J Clin Oncol 24:2084-91. 2006..CONCLUSION: Serious ixabepilone-induced neuropathy was relatively rare on the treatment schedule used. NFTs, such as JTH and GPT, may have utility for predicting PN, but further testing is needed... - A phase II trial with trastuzumab and pertuzumab in patients with HER2-overexpressed locally advanced and metastatic breast cancerJanice M Walshe
Breast Cancer Section, Medical Oncology Branch, Center for Cancer Research, National Institutes of Health, Bethesda, MD 20889, USA
Clin Breast Cancer 6:535-9. 2006 - Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancerSuparna Bonthala Wedam
Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, 8901 Wisconsin Avenue, Building 8, Rm 5101, Bethesda, MD 20889-5015, USA
J Clin Oncol 24:769-77. 2006..3% in extravascular-extracellular volume fraction (P = .002) were seen after bevacizumab alone. CONCLUSION: Bevacizumab has inhibitory effects on VEGF receptor activation and vascular permeability, and induces apoptosis in tumor cells... - Aromatase inhibitors--a triumph of translational oncologySandra M Swain
N Engl J Med 353:2807-9. 2005 - A pilot study to evaluate the vascular endothelial growth factor receptor tyrosine kinase inhibitor AZD2171 and chemotherapy in locally advanced and inflammatory breast cancerNeelima Denduluri
Breast Cancer Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Clin Breast Cancer 6:460-3. 2005 - Concepts and clinical trials of dose-dense chemotherapy for breast cancer Jennifer A Orzano
Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Department of Health and Human Services, Bethesda, MD, USA
Clin Breast Cancer 6:402-11. 2005..The strengths and limitations of CALGB 9741 will then be discussed before the presentation of future directions of research and recommendations for clinical practice today... - Development of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR)James J Lee
Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20889-5015, USA
Semin Oncol 32:S22-6. 2005..The development of these novel agents may evade MDR and may improve the outcome of patients with breast cancer... - Gene expression patterns and profile changes pre- and post-erlotinib treatment in patients with metastatic breast cancerSherry X Yang
Cancer Therapeutics Branch in Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20889, USA
Clin Cancer Res 11:6226-32. 2005.... - Review of flavopiridol, a cyclin-dependent kinase inhibitor, as breast cancer therapyAntoinette R Tan
Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD20889, USA
Semin Oncol 29:77-85. 2002..The interruption of the cell cycle through modulation of CDKs with an agent such as flavopiridol has potential therapeutic efficacy, especially in combination with chemotherapy...